SCG partners up with Frances Institut Pasteur to combat dengue with innovations to reduce mosquito breeding

Food and Healthcare Press Releases Tuesday June 11, 2019 14:36
Bangkok--11 Jun--SCG

Dr. Suracha Udomsak, Chief Technology Officer, on behalf of Chemicals Business, SCG, and Dr. Anavaj Sakuntabhai, Coordinator of the Defeat Dengue Program, Head of Structure, Functional Genetics of Infectious Diseases, representing Institut Pasteur, signed a collaborative research agreement for the development of anti-dengue innovations. The signing ceremony was held at the French Embassy of Thailand and presided over by Mr. Jacques Lapouge, the French Ambassador to Thailand. This collaboration is part of Institut Pasteur's Defeat Dengue Program, aims to prevent and eliminate dengue outbreaks, which are particularly frequent in tropical zones, such as Asia and Africa.

Mr. Jacques Lapouge, the French Ambassador to Thailand, said, "Mosquitoes and dengue fever are a serious problem in many parts of the world. According to the World Health Organization, about 50 million people worldwide are infected annually, and the number has been increasing every year. This collaboration between Thailand and France to take on this challenge marks a promising start and will lead to a technological exchange between Institut Pasteur, one of the world's leading research institute, and SCG, one of Thailand's most established companies."

Dr. Anavaj Sakuntabhai, Coordinator of the Defeat Dengue Program, Head of Structure, Functional Genetics of Infectious Diseases, Institut Pasteur, stated "Dengue is a global health problem. For over 20 years, Institut Pasteur has been conducting research to stop dengue outbreaks and found that successful prevention requires a collaborative effort, especially from business sector, as it can take research findings to communities and society at large. This project is an example of collaboration between a research institute and the business sector, and I hope that it will not only prove successful in Thailand but can also be scaled up globally."

Dr. Suracha Udomsak, Chief Technology Officer, Chemicals Business, SCG, remarked, "SCG strives to achieve sustainable development and believes that developing technologies in tandem with fostering open collaboration can lead to a better quality of life. It is an honor for us to have been trusted by Institut Pasteur to join the project, where we apply our expertise on functional materials as well as knowledge of materials science and design to develop the innovation to reduce mosquito breeding and the spread of dengue fever. This innovation can serve as an alternative preventive tool against the world's health issue of dengue.

The collaboration consists of the research and development of a mosquito trap and a functional material that helps improve the binding properties of compounds that inhibit mosquito breeding. When dissolved in water sources, the material can reduce the growth rate of mosquito larvae while posing no harm to other living creatures or the environment.

Chemicals Business, SCG and Institut Pasteur have also been working in collaboration with the Department of Medical Sciences, the Ministry of Public Health, and Ikari Trading (Thailand) Company Limited to administer mosquito attractants and conduct both lab and field tests on the efficiency of the mosquito trap before a public launch.


Latest Press Release

Most Thai consumers want to improve their diets and are open to healthier product reformulation

According to a new report by Food Industry Asia (FIA) and research firm IGD, almost all consumers in Thailand (99 per cent) are interested in improving their diets and a majority (82 per cent) are happy for products to be reformulated, provided that...

Kemin Launches New Vision and Logo for the Future

Global ingredient manufacturer sets sights on sustainably transforming 80 percent of the world by 2042 Today Kemin Industries, a global ingredient manufacturer, unveiled its new global vision and logo to align the company strategically for 2042 and...

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The...

Zeus Expands Portfolio with New Polyimide Family of Products

Products Include PI Tubing, PI Coated Wire, PI Glide(TM) Tubing, and PI Glide(TM) Coated Wire Zeus Industrial Products, Inc. (Zeus), a leading polymer solutions provider and material science innovator, has announced the introduction of a new polyimide...

SCG partners up with Frances Institut Pasteur to combat dengue with innovations to reduce mosquito breeding

Dr. Suracha Udomsak, Chief Technology Officer, on behalf of Chemicals Business, SCG, and Dr. Anavaj Sakuntabhai, Coordinator of the Defeat Dengue Program, Head of Structure, Functional Genetics of Infectious Diseases, representing Institut Pasteur,...

Related Topics